Dapagliflozin does not affect short-term blood pressure variability in patients with type-2 diabetes mellitus.

CONCLUSIONS: This study is the first to evaluate the effects of an SGLT-2 inhibitor on short-term BPV in patients with T2DM, showing no effect on dapagliflozin on all BPV indexes studied. PMID: 33277990 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33277990?dopt=Abstract

Source: American Journal of Hypertension - December 5, 2020 Category: Cardiology Authors: Papadopoulou E, Theodorakopoulou MP, Loutradis C, Tzanis G, Tzatzagou G, Kotsa K, Zografou I, Tsapas A, Karagiannis A, Sarafidis P Tags: Am J Hypertens Source Type: research